ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Noteworthy Friday Option Activity: CMG, BA, ALNY
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Alnylam Pharmaceuticals Becomes Oversold (ALNY)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category
As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Noteworthy Thursday Option Activity: CYH, SPHR, ALNY
Why Alnylam Pharmaceuticals Stock Is Sinking Today
Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.
Alnylam stock falls on Q4 topline miss (NASDAQ:ALNY)
Alnylam Pharmaceuticals (ALNY) reports lower-than-expected revenue for Q4 2023 and delays key Phase 3 readout due to changes in data analysis. Read more here.
Alnylam Pharmaceuticals Non-GAAP EPS of -$0.77 in-line, revenue of $439.72M misses by $2.58M (NASDAQ:ALNY)
Alnylam Pharmaceuticals reports Q4 non-GAAP EPS in line with expectations, but misses revenue estimates by $2.58M.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals Becomes Oversold (ALNY)
Investors growing more bullish on SMID cap biotech stocks (NASDAQ:ALNY)
Investors are more bullish about small and mid-cap biotech stocks this year, with Merus (MRUS) and Fusion (FUSN) viewed as most likely to outperform, according to TD Cowen.
Commit To Purchase Alnylam Pharmaceuticals At $150, Earn 36.7% Annualized Using Options
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Alnylam Pharmaceuticals Larger Than S&P 500 Component Equity Residential
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
